Drugs & Therapy Perspectives

, Volume 34, Issue 12, pp 560–566 | Cite as

Lesinurad in hyperuricaemia of gout: a profile of its use in the EU

  • Hannah A. BlairEmail author
  • Emma D. Deeks
Adis Drug Q&A


Up to 90% of gout patients experience low uric acid (UA) excretion rather than high UA production. The selective UA reabsorption inhibitor lesinurad (Zurampic®) is an effective and generally well tolerated option for the adjunctive treatment of hyperuricaemia in patients with gout who have not achieved target serum uric acid (sUA) levels with monotherapy with an adequate dosage of a xanthine oxidase inhibitor, a class of drugs that acts on UA production. In phase 3 trials of lesinurad + allopurinol in adults with gout inadequately responsive to allopurinol, and lesinurad + febuxostat in adults with tophaceous gout, the addition of once-daily oral lesinurad enabled many patients to achieve target sUA levels, and improved clinical parameters (e.g. tophus number/size) in the long term.



The manuscript was updated from Drugs & Aging 2017;34(5):401–1 [28], and was reviewed by: M. Bleckwenn, Institut für Hausarztmedizin, Medizinischen Fakultät der Universität Bonn, Bonn, Germany; A.L. Gaffo, University of Alabama at Birmingham, and Rheumatology Section, Birmingham VA Medical Center, Birmingham, AL, USA; M.J. Puszczewicz, Department of Rheumatology and Internal Medicine, Poznań University of Medical Sciences, Poznań, Poland; L. Roever, Clinical Research Department, Federal University of Uberlândia, Uberlândia, Brazil. During the peer review process, Grunenthal, the marketing-authorization holder of lesinurad, was also offered an opportunity to provide a scientific accuracy review of the data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with ethical standards


The preparation of this review was not supported by any external funding.

Conflict of interest

H. A. Blair and E. D. Deeks are employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.


  1. 1.
    Hui M, Carr A, Cameron S, et al. The British Society for Rheumatology guideline for the management of gout. Rheumatology. 2017;56(7):1246. Scholar
  2. 2.
    Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039–52.CrossRefGoogle Scholar
  3. 3.
    Bardin T, Richette P. Novel uricosurics. Rheumatology. 2018;57:i42–i46.CrossRefGoogle Scholar
  4. 4.
    Baker JF, Schumacher HR. Update on gout and hyperuricemia. Int J Clin Pract. 2010;64(3):371–7.CrossRefGoogle Scholar
  5. 5.
    Perez-Ruiz F, Martínez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73(1):177–82.CrossRefGoogle Scholar
  6. 6.
    Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42.CrossRefGoogle Scholar
  7. 7.
    Zurampic 200 mg film-coated tablets: EU summary of product characteristics. London: European Medicines Agency; 2017.Google Scholar
  8. 8.
    Zurampic® (lesinurad) tablets for oral use: US prescribing information. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2018.Google Scholar
  9. 9.
    Duzallo (allopurinol and lesinurad 200 mg/200 mg and 300 mg/200 mg) film-coated tablets: summary of product characteristics. London: European Medicines Agency; 2018.Google Scholar
  10. 10.
    Xin Y, Wang K, Jia Z, et al. Zurampic protects pancreatic β-cells from high uric acid induced-damage by inhibiting URAT1 and inactivating the ROS/AMPK/ERK pathways. Cell Physiol Biochem. 2018;47(3):1074–83.CrossRefGoogle Scholar
  11. 11.
    Miner J, Tan PK, Hyndman D, et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016;18(1):214.CrossRefGoogle Scholar
  12. 12.
    Shen Z, Rowlings C, Kerr B, et al. Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males. Drug Des Devel Ther. 2015;9:3423–34.CrossRefGoogle Scholar
  13. 13.
    Baumgartner S, Yeh LT, Shen Z, et al. The effect of lesinurad in combination with allopurinol on serum uric acid levels in patients with gout. J Clin Pharmacol. 2018;58(9):1164–70.CrossRefGoogle Scholar
  14. 14.
    Fleischmann R, Kerr B, Yeh LT, et al. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology. 2014;53(12):2167–74.CrossRefGoogle Scholar
  15. 15.
    Perez-Ruiz F, Sundy JS, Miner JN, et al. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. 2016;75(6):1074–80.CrossRefGoogle Scholar
  16. 16.
    Bardin T, Keenan RT, Khanna PP, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis. 2017;76(5):811–20.CrossRefGoogle Scholar
  17. 17.
    Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis Rheumatol. 2017;69(1):203–12.CrossRefGoogle Scholar
  18. 18.
    Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial. Arthritis Rheumatol. 2017;69(9):1903–13.CrossRefGoogle Scholar
  19. 19.
    Saag KG, Bardin T, So A, et al. Analysis of gout subjects receiving lesinurad and allopurinol combination therapy by baseline renal function [abstract no. 2112]. Arthritis Rheumatol. 2015;67(Suppl 10).Google Scholar
  20. 20.
    Bardin T, Karra RG, So A, et al. Lesinurad (LESU) adjunctive therapy with allopurinol (ALLO) in patients not responding to ALLO monotherapy: pooled post hoc safety and efficacy analysis in a patient subgroup using concomitant diuretics at baseline (BL) [abstract no. SAT0374]. Ann Rheum Dis. 2018;77(Suppl 2):1050.Google Scholar
  21. 21.
    Bardin T, Dalbeth N, Terkeltaub R, et al. Clinical response of tophus and flares to extended use of lesinurad in combination with a xanthine oxidase inhibitor in patients with gout [abstract no. 209]. Arthritis Rheumatol. 2016;68(Suppl 10).Google Scholar
  22. 22.
    Saag KG, Becker MA, Storgard C, et al. Examination of serum uric acid (SUA) lowering and safety with extended treatment with lesinurad and allopurinol in subjects with gout [abstract no. THU0495]. Ann Rheum Dis. 2016;75(Suppl 2):371.CrossRefGoogle Scholar
  23. 23.
    Terkeltaub R, Saag KG, Goldfarb DS, et al. Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. Rheumatology. 2018.
  24. 24.
    Terkeltaub R, Malamet R, Bos K, et al. Renal safety of lesinurad: a pooled analysis of phase III and extension studies [abstract no. THU0455]. Ann Rheum Dis. 2017;76 (Suppl 2):379–80.Google Scholar
  25. 25.
    Klein RW, Kabadi S, Cinfio FN, et al. Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective. J Comp Eff Res. 2018.
  26. 26.
    Ruggeri M, Basile M, Drago C, et al. Cost-effectiveness analysis of lesinurad/allopurinol versus febuxostat for the management of gout/hyperuricemia in Italy. Pharmacoeconomics. 2018;36(5):625–36.CrossRefGoogle Scholar
  27. 27.
    Perez-Ruiz F, Kandaswamy P, Karra Gurunath R, et al. A summary of clinical evidence for commonly used uricosurics for gout in Europe [abstract no. SAT0360]. Ann Rheum Dis. 2018;77(Suppl 2):1045.Google Scholar
  28. 28.
    Deeks ED. Lesinurad: a review in hyperuricaemia of gout. Drugs Aging. 2017;34(5):401–10.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations